Myosarcoma — Trials · CancerIndex

Clinical trials

Registered studies

325 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 106
Recruiting: 58
Ph III recruiting: 6
Growth YoY: −35%
Industry share: 11%
Top sponsor: National Cancer Institute (NCI)
Termination share: 31.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (42)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05204524	Temozolomide for Injection Combined With Epirubicin in First-line Treatment of Leiomyosarcoma	unknown	N/A	28	Chinese Academy of Medical SciencesOTHER	1	Jan 24, 2022	clinicaltrials

Data updated 22 days agoSource updated Jan 24, 2022source: clinicaltrials